I'm not talking only about these 717 patients. I said this;
Now this is ONE trial of ONE compound (Xeljanz). It has rune more lengthy phase 3 trials. Add to this the fact that this medicine is actually on the market now. Add to this also that multiple other JAK inhibitors are running clinical trials
I'm talking about hundreds of patients more if not thousand of patients. Yes not everyone of them will have Androgenetic Alopecia, not everyone of them will be obviously men. However a pretty big % will have Androgenetic Alopecia to some degree.These professional medical people don't have to argue that tofacitinib hasn't failed orally at the dosages tested for Androgenetic Alopecia, because it has. Do you want me to actually contact A.M Christiano and see if she wants to argue otherwise vs me? I can do that if you want. Would that convince you?
Hair regrowth is something that doesn't go unnoticed dude. There is no difference between a norwood 2 and a norwood 6. The basic principle is the same. A norwood 2 wants to have reversal of miniaturization in the norwood 2 area and the norwood 6 wants to have it in the norwood 6 area.
After two months on tofacitinib at 10 mg daily, the patient’s psoriasis showed some improvement, and the man had grown scalp and facial hair — the first hair he’d grown there in seven years. After three more months of therapy at 15 mg daily
Already in the trial I mentioned we see these dosages. Actually in the trial one group had 2x 10mg which amounts to 20mg a day, which is even a bigger dosage than in the AA guy. Here is another phase 3 trial of tofacitinib;
The Oral Step study enrolled 399 patients with moderate-to-severe active RA who had previously demonstrated an inadequate response to at least one TNF inhibitor. Participants were randomized to receive 5 mg or 10 mg tofacitinib twice daily, or placebo, in addition to stable background methotrexate. All placebo-treated patients were switched over to tofacitinib therapy at the three-month mark.
And here is another one for psoriasis oral for a 1 year period
https://www.aad.org/eposters/Submissions/getFile.aspx?id=2216&type=sub. With
N= 745 and
N= 741 on
10mg and
20mg daily, almost
1500 patients.
If we only count these trials I just mentioned this is already over
2500 people. Add to this actually more trials that have run, add to this other JAK inhibitors that are in clinical trials and add to this that Xeljanz is actually launched on the market and in use by patients. We are talking about thousands of people here.
If you still argue that Xeljanz works orally for Androgenetic Alopecia at these dosages then you believe in fairy tales, don't you think?
Am I excluding here that perhaps Xeljanz won't work at even higher oral dosages or topically? No but clearly at these dosages it doesn't do sh*t at least orally. I also think the chances of it working in bigger dosages or topically is incredibly small, but we'll see. I have other reasoning behind this than only looking at the findings of Christiano. All she has is a rodent model which says nothing, nada. She wouldn't argue otherwise with this also. In fact she has actually mentioned recently herself that a rodent model doesn't translate to Androgenetic Alopecia.
Additionally, Christiano says delivery is where the opportunities lie for an Androgenetic Alopecia test protocol. She says it would be preferable that the drug remain in the dermis nearest follicles for longer than 5 minutes. Christiano-Jahoda method using 3d speroids for delivery of JAK inhibitors hasn't been tried on people yet let lone those with Androgenetic Alopecia. Short time to fail, she says. We should know sooner than later.
Fine it's possible, weak argumentation imo. She has a point there. Like I said increased concentrations might have a other effect. I doubt it though. However again orally at these dosages described it's just not going to work. Where does she base her observations on though? That's right mice.
Finally, there are such things as confidentiality/disclosure agreements between companies and academia and doctors. It could even be a case that they, and perhaps through anecdotal and other evidence as you say should exist, already know the effects Xeljanz/Tofacitinib has on people with Androgenetic Alopecia but are restricted from publishing or broadcasting that information to the public. A lot of money and reputations at stake with a cure for Androgenetic Alopecia.
I think it's illegal to say otherwise. If hair growth would get noted either by patient or observer such findings need to be described in the clinical trial. I don't know this for sure though. Anyway they would be pretty damn happy to report such findings. Thinking that it would be kept secret is typical tinfoil hat thinking. It would be all over the news just as the AA guy. It's patented anyway.
All in all I wouldn't get your hopes up to much with this one. But time will tell. I hope I'm wrong obviously.